Astellas’s Phase III SPOTLIGHT trial studying zolbetuximab in CLDN18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma returned positive results.
https://www.pharmalive.com/wp-content/uploads/2021/09/Another-Patient-Dies-Following-Treatment-with-Astellas-Experimental-Gene-Therapy-BioSpace-9-14-21.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-11-17 10:18:092022-11-17 10:18:09Astellas scores late-phase win in CLDN18.2-positive gastric cancer
